Dr. Hayley McLoughlin is a Research Assistant Professor in the University of Michigan Neurology Department. She earned her Neuroscience doctoral degree in 2013 from the University of Iowa in Dr. Beverly Davidson's laboratory and completed a postdoctoral research fellowship under the guidance of Dr. Henry (Hank) Paulson at the University of Michigan. In her postdoc, she assessed the efficacy of antisense oligonucleotide therapy in mouse models of Spinocerebellar Ataxia type 3/Machado-Joseph disease (SCA3/MJD). In 2016, she was appointed to faculty at the University of Michigan where her lab focuses on establishing pathogenic mechanisms and therapeutic interventions for neurodegenerative diseases with particular emphasis toward the polyglutamine disease, SCA3. SCA3 is a progressive, dominantly inherited neurodegenerative disease for which there currently is no treatment. Dr. McLoughlin continues to lead SCA3 preclinical efforts toward antisense oligonucleotide (ASO) gene silencing and viral-mediated RNAi in collaboration with industry partners. In hopes of identifying additional routes for therapeutic intervention, discovery of novel disease biomarkers, and to provide broader insight into the polyglutamine diseases beyond SCA3, the McLoughlin lab interrogates disease mechanisms using a variety of SCA3 cellular and animal disease models as well as human tissue and biofluid samples. Current and recently completed funding sources of the lab include the National Ataxia Foundation Young Investigator Award, NAF SCA3 Special Projects Award, MICHR Pathways to Independence Pilot Award, NINDS-R21 NS111154, NINDS R01 NS112191, and NINDS-U01 NS106670.
Areas of Interest
SCA3/MJD, Ataxia, gene therapy, ASO, RNAi, protein aggregation, biomarker discovery and development
- PhD, Neuroscience, University of Iowa, 2013
- NIH T32 NRSA Post-doctoral Fellowship Ruth L. Kirschstein, 2014-2016